ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons"

  • Abstract Number: 1525 • 2015 ACR/ARHP Annual Meeting

    Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes

    Shogo Banno1, Shiho Iwagaitsu2, Taio Naniwa3, Hironobu Nobata4, Hirokazu Imai4, Shinya Tamechika2, Shinji Maeda2 and Akio Niimi2, 1Rheumatology and Nephrology, Aichi Medical University School of Medicine, Aichi-prefecture, Japan, 2Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya City, Japan, 3Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya city, Japan, 4Rheumatology and Nephrology, Aichi Medical University School of Medicine, Nagakute City, Japan

    Background/Purpose: We aimed to evaluate the performance of QFT-GIT and T-SPOT.TB assays to predict the risk of latent tuberculosis infection (LTBI) in Japanese rheumatoid arthritis…
  • Abstract Number: 1805 • 2015 ACR/ARHP Annual Meeting

    Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

    Jeffrey Riggs1, Brian Naiman2, Jing Zhang1, Yan Xu1, Inna Vainshtein3, Carl Hay1, Kevin Schifferli1, Pina Cardarelli4, Meina Liang5, Lorin Roskos6, Jane Connor7, Roland Kolbeck8, Anthony Coyle9 and Michael Fung1, 1MedImmune LLC, Gaithersburg, MD, 2Research, MedImmune LLC, Gaithersburg, MD, 3MedImmune LLC, Hayward, CA, 4Medarex, Sunnyvale, CA, 5PKPD&Bioanalysis, MedImmune LLC, Hayward, CA, 6MedImmune LLC, Mountain View, CA, 7Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, 8Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, 9Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA

    Background/Purpose: Increased type I interferon (IFN) activities are associated with the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab, a fully human, IgG1 κ monoclonal antibody…
  • Abstract Number: 1617 • 2014 ACR/ARHP Annual Meeting

    Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes

    Zhongbo Jin1, Mark A. Jensen2, Jessica M. Dorschner1, Danielle Vsetecka1, Shreyasee Amin3, Ashima Makol4, Floranne C. Ernste5, Thomas Osborn6, Kevin G. Moder4, Vaidehi Chowdhary3 and Timothy B. Niewold1, 1Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 2Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 6Dept of Rheumatology, Mayo Clinc, Rochester, MN

    Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE).  IFN gene expression signatures have been observed in whole blood and mixed peripheral…
  • Abstract Number: 872 • 2014 ACR/ARHP Annual Meeting

    Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia

    Danieli Andrade1, Mimi Kim2, Luz P. Blanco3, S. Ananth Karumanchi4, Gloria Koo5, Patricia M. Redecha6, Kyriakos A. Kirou1, Angela M. Alvarez7, Melissa J. Mulla7, Mary K. Crow8, Vikki Abrahams7, Mariana J. Kaplan3 and Jane E. Salmon9, 1Hospital for Special Surgery, New York, NY, 2Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 3Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, 6Rheumatology Research, Hospital for Special Surgery, New York, NY, 7Yale School of Medicine, New Haven, CT, 8Department of Medicine, Hospital for Special Surgery, New York, NY, 9Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in…
  • Abstract Number: 861 • 2014 ACR/ARHP Annual Meeting

    Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus

    Clayton Sontheimer1 and Keith B. Elkon2, 1Pediatric Rheumatology, University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions often contain plasmacytoid dendritic cells (pDC). The mechanisms…
  • Abstract Number: 764 • 2014 ACR/ARHP Annual Meeting

    ERG and FLI1 in Systemic Sclerosis-Associated Pulmonary Complications

    Rong Han and Maria Trojanowska, Arthritis Center, Boston University, Boston, MA

    Background/Purpose: Pulmonary arterial hypertension (PAH) and pulmonary fibrosis (PF) are the two major lung complications associated with the autoimmune disease systemic sclerosis (SSc), and constitute…
  • Abstract Number: 641 • 2014 ACR/ARHP Annual Meeting

    Peptidylarginine Deiminase Inhibition Mitigates NET Formation and Protects Against Kidney, Skin, and Vascular Disease in Lupus-Prone MRL/Lpr Mice

    Jason S. Knight1, Venkataraman Subramanian2, Alexander A. O'Dell1, Srilakshmi Yalavarthi1, Wenpu Zhao3, Carolyne K. Smith3, Jeffrey B. Hodgin4, Paul Thompson2 and Mariana J. Kaplan3, 1Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2The Scripps Research Institute, Jupiter, FL, 3Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Department of Pathology, University of Michigan, Ann Arbor, MI

    Background/Purpose:  An imbalance between neutrophil extracellular trap (NET) production and NET degradation has been observed in systemic lupus erythematosus (SLE), potentially contributing to autoantigen externalization,…
  • Abstract Number: 2979 • 2014 ACR/ARHP Annual Meeting

    Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjogrens Syndrome

    Naomi I Maria1, Cornelia G. van Helden-Meeuwsen1, Eline C. Steenwijk1, Arne S. IJpma2, Wouter Beumer1, Zana Brkic1, Virgil A. Dalm1, Paul L. van Daele1, P. Martin van Hagen1, Peter J. van der Spek2, Hemmo A. Drexhage1 and Marjan A. Versnel1, 1Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by autoantibodies targeting RNA-associated antigens, anti-SSA/SSB. The IFN-signature is present in over half of…
  • Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting

    Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis

    Priyanka Vashisht1, Jessica M. Dorschner2, Mark A. Jensen3, Beverly Chrabot4, Theresa Wampler Muskardin5, Marlena Kern6, Tetrad Investigators7, ABCoN Consortium8, S. Louis Bridges Jr.9,10, P.K. Gregersen11 and Timothy B. Niewold2, 1Division of Rheumatology and Department of Immunology, University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 3Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 4Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 5Div of Rheumatology, Mayo Clinic, Rochester, MN, 6North Shore Univ Hospital, Feinstein Institute for Medical Research, Manhasset, NY, 7AL, 8NY, 9University of Alabama at Birmingham, Birmingham, AL, 10Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 11The Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA).  Previous studies have suggested that circulating type I interferon (IFN)…
  • Abstract Number: 2843 • 2014 ACR/ARHP Annual Meeting

    SLE Patients Carrying a Disease-Associated PTPN22 R620W Variant Show Reduced Interferon-Inducing Capacity

    Yaya Wang1, David Ewart2, Ami Yamamoto2, Emily C. Baechler1, Parastoo Fazeli3 and Erik J. Peterson2, 1Medicine, University of Minnesota, Minneapolis, MN, 2University of Minnesota, Minneapolis, MN, 3Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN

    Background/Purpose Type 1 interferons (IFN) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Increased expression of IFN-regulated genes, termed the IFN-signature, correlates with…
  • Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting

    Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome

    Yasin Keskin1, Emire Seyahi2, Cagri Poyraz3, Serdal Ugurlu1, Yilmaz Ozyazgan4 and Hasan Yazici5, 1Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 3Department of Psychiatry, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Istanbul, Turkey, 4Department of Ophthalmology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

    Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…
  • Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting

    Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients

    Jacob Sode1,2,3, Ulla Vogel4, Steffen Bank5,6, Paal Skytt Andersen7, Merete Lund Hetland8,9, Henning Locht3, Niels H. H. Heegaard10,11 and Vibeke Andersen1,5,12,13, 1Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, 2Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, 3Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, 4National Research Centre for the Working Environment, Copenhagen, Denmark, 5Medical Department, Viborg Regional Hospital, Viborg, Denmark, 6Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, 7Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 9Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 10Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 11Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, 12Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, 13Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark

    Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…
  • Abstract Number: 2093 • 2014 ACR/ARHP Annual Meeting

    Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone-Related Suppression of Type I Interferon Response Gene Expression

    Tamarah D. de Jong1, Saskia Vosslamber1, Marjolein Blits1, Gertjan Wolbink2, Michael T. Nurmohamed2,3, Connie J. van der Laken4, Gerrit Jansen5, Alexandre E. Voskuyl5 and Cornelis L. Verweij6, 1Pathology, VU University Medical Center, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 5Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 6Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose Elevated type I IFN response gene (IRG) expression has been described to be clinically relevant in predicting the non-response to rituximab in rheumatoid arthritis…
  • Abstract Number: 1793 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study

    Benjamin Seeliger1, Martin Foerster1, Anne Moeser1, Janett Happe1, Claus Kroegel1 and Thomas Neumann2, 1Jena University Hospital, Internal Medicine I, Jena, Germany, 2Jena University Hospital, Internal Medicine III, Jena, Germany

    Background/Purpose: To evaluate the efficiency and safety of IFN-alpha in induction and maintenance of remission in patients with EGPA and to describe its effects on…
  • Abstract Number: 1625 • 2014 ACR/ARHP Annual Meeting

    Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles

    Kimberly Carroll1, Elizabeth Mitton-Fitzgerald1, Brittany Bettendorf2, Claudia Gohr1, Mary E. Cronin1 and Ann K. Rosenthal3, 1Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 2Internal Medicine/Pediatrics, Medical College of Wisconsin, Wauwatosa, WI, 3Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Microparticles (MPs) are circulating membrane-bound vesicles derived from blood and endothelial cells via a highly regulated process. They are immunomodulatory and have been implicated…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology